Remove Compounding Remove Drug Pricing Remove Pharmacy Management
article thumbnail

Op-Ed: States Are Leading the Way on PBM Reform. Here’s How.

Pharmacy Times

Author(s): Debra Patt, MD, PhD, MBA , Jeff Hunnicutt Key Takeaways PBMs, initially designed to reduce costs, now inflate drug prices and dominate the market, impacting patient access to affordable medications. Here’s How.

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

This pathway’s expanded use and shifting Centers for Medicare & Medicaid Services (CMS) policies are reshaping reimbursement practices and therapeutic equivalence standards for 505(b)(2) drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharmacy Policy Updates for June 2025

Pharmacy Times

According to Trump, patients could see cost reductions of 30% to 80%, but experts question the feasibility and practicality of implementing such a policy within the complex United States drug pricing and supply system. Kennedy Jr, is permitted to develop a new rule that ties American drug prices to those of other nations.

article thumbnail

Do We Really Pay More for Prescription Drugs in the United States?

Pharmacy Times

Trump signed an executive order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” with the objective of lowering drug prices, namely on branded drug products, for American consumers. How Does Drug Pricing in the US Compare With Other Countries?

article thumbnail

Statement from the Center for Innovation & Value Research

Pharmacy Times

However, as momentum builds around aggressive policy proposals like the Most Favored Nation (MFN) pricing model, we urge policymakers to pause and ask a critical question: What do these policies mean for patients? Models like MFN and International Reference Pricing (IRP) risk importing foreign solutions into a deeply complex U.S.

article thumbnail

Examining the One Big Beautiful Bill Act on Prescription Drugs: Benefits and Criticisms

Pharmacy Times

2 Although seen as restoring incentives for rare disease research, critics argue it perpetuates high pricing and industry-friendly policy. The OBBB expanded the list of drugs exempt from negotiation and delayed implementation of new price controls.